A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|April 27, 2022
Daily Medication Pearl: Finasteride (Propecia)
Author(s)Saro Arakelians, PharmD
Finasteride (Propecia) is a 5α-reductase inhibitor indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only.
Advertisement
Medication Pearl of the Day: Finasteride (Propecia)
Indication: Finasteride (Propecia) is a 5α-reductase inhibitor indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only.
Insight:
- Dosing:Take 1 tablet once daily.
- Dosage forms: 1 mg tablets.
- Adverse events:The most common adverse reactions reported in ≥1% of patients treated with finasteride are decreased libido, erectile dysfunction, and ejaculation disorder.
- Mechanism of action: Finasteride is a competitive and specific inhibitor of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into DHT
- Manufacturer: Merck
Source
Advertisement
Related to this article
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg vs placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5